Special use-results survey of ENAROY Tablets(long-term use)
Not Applicable
Recruiting
- Conditions
- Anemia associated with CKD
- Registration Number
- JPRN-jRCT2031210549
- Lead Sponsor
- Patient Safety and Pharmacovigilance Dept.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1500
Inclusion Criteria
(1) Patients using Enaroy for the first time for nephrogenic anemia
(2) Patients must provide informed consent before the start
Exclusion Criteria
none
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method -Incidence of onset of thromboembolism<br>-Incidence of onset of hypertension<br>-Incidence of cardiovascular events (excluding thromboembolism)<br>-Incidence of onset of retinal hemorrhage<br>-Incidence of onset of malignant tumor<br>-Incidence of progressed disease in patients with autosomal dominant polycystic kidney disease (ADPKD)
- Secondary Outcome Measures
Name Time Method